Compare Futu Holdings Ltd (FUTU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Novo Nordisk A/S — how do they compare? Futu Holdings Ltd trades at $110.3 (market cap $15.38B), while Novo Nordisk A/S trades at $38.11 (market cap $168.73B). The key difference: Novo Nordisk A/S is far larger — about 11× Futu Holdings Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Novo Nordisk A/S for 116 Days on average.
| FUTU | NVO | |
|---|---|---|
Market Cap | $15.38B | $168.73B |
Volume | 1,475,116 | 13,531,267 |
Sector | Financials | Health |
52-Week High | $199.04 | $63.98 |
52-Week Low | $89.76 | $35.29 |
Typical Hold Time | 34 Days | 116 Days |
Enterprise Value | $15.73B | $183.05B |
Dividend Yield | 2.37% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $108.76, down 3.93% on the day amid a bearish technical signal, though it remains above key support near $107. The company reported strong Q2 2026 earnings with a beat on EPS of $3.33 versus $2.98 expected, continuing robust revenue growth that reached $22.85 billion in 2025. However, a securities class action lawsuit deadline on August 25, 2026, adds near-term uncertainty.
The outlook is mixed: solid fundamentals with a low P/E of 10.95 and high net margin of 42.92% support upside potential, but technical weakness and legal overhangs pose risks. Analyst consensus is bullish with a 33.7% upside target, yet investors must weigh growth against litigation and market sentiment pressures.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
